$Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial$

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

Bibliographic Details
Main Authors:	De Botton, S, Risueño, A, Schuh, AC, Lowenberg, B, Kim, H-J, Vyas, P, Wei, AH, Stein, EM, Dohner, H, Fathi, AT, Dinardo, CD, Martin Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
Format:	Conference item
Language:	English
Published:	American Society of Clinical Oncology 2022

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

Similar Items